Inactive Instrument

Highlights Emmaus Life Sciences, Inc. Other OTC

Equities

EMMA

US29137T1016

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)	02-02	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M	11-14	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Emmaus Life Sciences, Inc Receives Marketing Authorization for EndariÂ® in Oman	13/07/23	CI
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority	31/05/23	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $6.8M	15/05/23	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Emmaus Life Sciences, Inc. Receives Kuwaiti Marketing Authorization	07/12/22	CI
Emmaus Life Sciences, Inc. Receives Endari Marketing Authorization from the Qatar Ministry of Public Health	17/11/22	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $3.2M	13/05/22	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22	CI
Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari	23/03/22	CI
Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology Annual Meeting	14/12/21	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5.8M	12/11/21	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Emmaus Life Sciences, Inc. Other OTC

Equities

EMMA

US29137T1016

Highlights

Filters